Company intelligence / Profile preview

Tuojie Biotech

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Tuojie Biotech is advancing multiple small molecule and oligonucleotide drugs for oncology, cardiovascular, metabolic, and immune disorders. Pipeline includes CDK inhibitors for cancer and inflammatory disorders, LPAR1 antagonists for metabolic/inflammatory/fibrotic disorders, mineralocorticoid receptor antagonists for cardiovascular disease, and a GLP-1/GIP dual agonist for obesity, with some candidates in Phase 1. Clinical results have yet to be published for most pipeline assets.

Therapeutic areas: ImmunologyEndocrinologyMetabolic DisordersInfectious DiseasesCardiovascularOtherOncology
Modalities: Small moleculeOligonucleotidePeptidesMonoclonal antibodySynthetic peptideBiological products
Industry: Biotech

Drug pipeline

25 assets

TJ-062

Preclinical

24 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Tuojie Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tuojie Biotech.

Explore the full profile